Korea University Anam Hospital
Seoul, South Korea
70 recruiting
Showing 1–20 of 119 trials
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled484 locationsNCT05878769
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Incyte Corporation700 enrolled273 locationsNCT07284849
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled384 locationsNCT07062965
Recruiting
Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ovarian Cancer
Incyte Corporation466 enrolled157 locationsNCT07214779
Recruiting
Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
BioNTech SE558 enrolled83 locationsNCT07173751
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled380 locationsNCT05920356
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled653 locationsNCT06424288
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda150 enrolled108 locationsNCT06948318
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled638 locationsNCT06935370
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled82 locationsNCT06510374
Recruiting
Not Applicable
CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension
Hypertension
Korea University Anam Hospital400 enrolled3 locationsNCT07465549
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled56 locationsNCT06847542
Recruiting
Phase 3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
BioNTech SE480 enrolled132 locationsNCT06340568
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled205 locationsNCT06801834
Recruiting
Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled286 locationsNCT06252649